Research To Practice | Oncology Videos

Latest Episodes:

Breast Cancer | Oncology Today with Dr Neil Love: Recent Updates in the Management of HER2-Low Breast Cancer Aug 02, 2022

Show notes

Efficacy data with T-DXd from the DESTINY-Breast04 trial for patients with HER2-low breast cancer; incidence and biologic relevance of HER2 mutations in breast cancer (0:00)
Current and potential clinical roles for liquid biopsy in breast cancer; cardiac toxicity with T-DXd in the DESTINY-Breast04 trial (6:10)
Safety profile of T-DXd from the DESTINY-Breast04 trial (11:09)
Incidence and management of interstitial lung disease caused by T-DXd (14:54)
Disease- and patient-specific factors and other considerations in the sequencing of chemotherapy, antibody-drug conjugates, tyrosine kinase inhibitors, SERDs (selective estrogen receptor degraders) and CDK4/6 inhibitors for breast cancer (21:45)
Case: A woman in her early 60s with new lobular Stage II breast cancer 20 years after previous breast cancer on the same side (28:39)
Case: A woman in her late 20s with a right breast lump and a strong family history of breast cancer (36:12)
Case: A woman in her late 30s presenting with right axillary pain who experiences disease progression on T-DM1 and then receives T-DXd (46:09)
Future of novel antibody-drug conjugates alone and in combination with immunotherapy for breast cancer (52:35)

CME information and select publications

Breast Cancer | Oncology Today with Dr Neil Love: Recent Updates in the Management of HER2-Low Breast Cancer (Companion Faculty Lecture) Aug 02, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Shanu Modi, incluing the following topics:

Biology and incidence of HER2-low breast cancer (0:00)
Emerging clinical trial data with targeted therapies for HER2-low breast cancer (4:53)
Future directions in the treatment of HER2-low breast cancer (16:58)

CME information and select publications

Non-Small Cell Lung Cancer | Oncology Today with Dr Neil Love: Management of Unresectable Stage III Non-Small Cell Lung Cancer Aug 01, 2022

Show notes

Featuring an interview with Drs Jeffrey Bradley and David Spigel, including the following topics:

Clinical Investigator Perspectives on the Management of Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (0:00)
Multimodality Management Options for Patients with Unresectable Stage III NSCLC — Jeffrey Bradley, MD (35:46)
Integration of Immune Checkpoint Inhibition into the Management of Unresectable Stage III NSCLC — David R Spigel, MD (1:03:41)
Case presentations by Dr Bradley (1:25:27)
Case Presentations by Dr Spigel (1:37:44)

CME information and select publications

Meet The Professor: Optimizing the Management of Hepatobiliary Cancers — Part 1 Jul 29, 2022

Show notes

Featuring perspectives from Prof Ghassan Abou-Alfa, including the following topics:

Introduction (0:00)
Case: A woman in her early 50s with metastatic hepatoid carcinoma of the ovary with an FGFR fusion — Syed M Ahmed, MD, PhD (2:56)
Key recent data sets (5:59)
Case: A man in his mid 60s with a history of Child-Pugh B cirrhosis and Grade 1 esophageal varices who is receiving atezolizumab/bevacizumab for multifocal HCC — Raji Shameem, MD (22:28)
Case: A man in his late 60s with previously treated HCC cirrhosis who is now diagnosed with potentially resectable HCC — Syed F Zafar, MD (29:30)
Case: A woman in her late 70s receiving adjuvant anastrozole for Stage I breast cancer who is now receiving atezolizumab/bevacizumab for metastatic HCC — Sunil Gandhi, MD (33:41)
Case: A man in his late 70s with metastatic HCC and portal vein thrombosis receiving atezolizumab/bevacizumab (NGS [next-generation sequencing] with PIK3CA mutation, PD-L1 50%) — Susmitha Apuri, MD (35:47)
Management of Biliary Tract Cancers (40:18)
Case: A man in his late 50s with resected Stage IIB gallbladder cancer s/p adjuvant capecitabine who now has metastatic disease (HER2-positive; MSS, PD-L10) — Nasfat Shehadeh, MD (44:01)
Case: A woman in her early 40s with a history of ductal carcinoma in situ and family history of breast cancer, now with metastatic cholangiocarcinoma (NGS with IDH2 mutation) — Joanna Metzner-Sadurski, MD (53:41)

CME information and select publications

Genitourinary Cancers | Oncology Today with Dr Neil Love: Key Presentations on Genitourinary Cancers from the 2022 ASCO Annual Meeting Jul 28, 2022

Show notes

Featuring an interview with Dr Sandy Srinivas, including the following topics:

Rationale for and efficacy data from the Phase II SALV-ENZA trial of salvage radiation therapy with enzalutamide or placebo for high-risk recurrent hormone-sensitive prostate cancer (0:00)
Results from clinical trials evaluating abiraterone, docetaxel or apalutamide for patients with hormone-sensitive prostate cancer (3:29)
TheraP trial: Three-year overall survival with 177Lu-PSMA-617 versus cabazitaxel for metastatic hormone-resistant prostate cancer (8:31)
Clinical data with abiraterone acetate in combination with PARP inhibition for patients with metastatic hormone-resistant prostate cancer: Results from the PROpel and MAGNITUDE trials (13:54)
Current role of neoadjuvant chemotherapy with immunotherapy for patients with metastatic urothelial bladder cancer (UBC); updated long-term outcomes with enfortumab vedotin from the EV-301 trial (20:23)
Clinical pearls for preventing and managing adverse events with erdafitinib, sacituzumab govitecan or enfortumab vedotin in patients with UBC (25:23)
HER2 expression in UBC and emerging data with the novel HER2-targeted antibody-drug conjugate RC48 alone and in combination with toripalimab; tolerability of antibody-drug conjugates (30:53)
Follow-up efficacy and safety data from the KEYNOTE-564 trial; practical implications of the safety data with adjuvant pembrolizumab for renal cell carcinoma (RCC) (36:16)
Emerging data with the novel agent belzutifan for advanced clear cell RCC (40:11)
Current practice and potential advances in the first-line treatment of metastatic RCC (44:25)

CME information and select publications

Genitourinary Cancers | Oncology Today with Dr Neil Love: Key Presentations on Genitourinary Cancers from the 2022 ASCO Annual Meeting (Companion faculty lecture) Jul 28, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Sandy Srinivas, including the following topics:

Results from the Phase II SALV-ENZA trial evaluating salvage radiation therapy with enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy (0:00)
Updated overall survival outcomes from the ENZAMET trial of enzalutamide for metastatic hormone-sensitive prostate cancer (3:48)
Genomic alterations associated with overall survival for patients with metastatic castration-sensitive prostate cancer treated with apalutamide or placebo with androgen deprivation therapy in the TITAN study (7:43)
Three-year overall survival with 177Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel (9:56)
Further results from the Phase III PROpel trial of abiraterone with olaparib for patients with metastatic castration-resistant prostate cancer (12:32)
Results from the MAGNITUDE study of niraparib with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (15:39)
The role of perioperative chemoimmunotherapy in muscle-invasive urothelial carcinoma (18:23)
Long-term outcomes from the Phase III EV-301 trial: Enfortumab vedotin versus chemotherapy for patients with previously treated advanced urothelial carcinoma (21:44)
First results from trials of the novel anti-HER2 antibody-drug conjugate RC48 alone and in combination with the anti-PD-1 antibody toripalimab; results from cohorts 3, 4 and 5 of the COSMIC-021 trial evaluating cabozantinib in combination with atezolizumab for urothelial carcinoma (23:12)
Updated analyses of exploratory endpoints from the KEYNOTE-564 and CheckMate 9ER trials in renal cell carcinoma (RCC) (26:37)
Updates on tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy and other novel approaches for patients with RCC (29:08)

CME information and select publications

Acute Myeloid Leukemia and Myelodysplastic Syndromes | Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes – A Review of the 2022 ASCO Annual Meeting and EHA Congress Jul 27, 2022

Show notes

Featuring perspectives from Dr Richard Stone, including the following topics:

Introduction: RATIFY trial in perspective (0:00)
Treatment with FLT3 inhibitors (7:00)
Anti-CD47 antibody: Magrolimab (23:04)
Anti-TIM-3 antibody: Sabatolimab (31:23)
CAR T-cell therapy for acute myeloid leukemia (34:53)
Targeted therapy with IDH inhibitors (37:31)
New myelodysplastic syndromes classification system (41:20)
Hypomethylating agents/venetoclax (45:11)
CPX-351 (49:14)
Other key data sets (50:59)

CME information and select publications

Hodgkin and Non-Hodgkin Lymphomas | What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial Participation in Hodgkin and Non-Hodgkin Lymphomas Jul 22, 2022

Show notes

Featuring perspectives from Dr Christopher Flowers and Ms Robin Klebig, including the following topics:

Management of Diffuse Large B-Cell Lymphoma (0:00)
Caring for Patients with Hodgkin Lymphoma (32:59)
Treatment for Follicular Lymphoma (44:17)
Managing Mantle Cell Lymphoma (58:12)

NCPD information and select publications

Cholangiocarcinoma | Oncology Today with Dr Neil Love: Management of Cholangiocarcinoma and Other Biliary Tract Cancers (Companion Faculty Lecture) Jul 21, 2022

Show notes

Featuring a slide presentation and related discussion from Professor Juan Valle, including the following topics:

Management of biliary tract cancers (BTCs) with targetable mutations (0:00)
Management of BTCs without targetable mutations (13:59)
Novel targets and treatments for cholangiocarcinoma and other BTCs (20:19)

CME information and select publications

Cholangiocarcinoma | Oncology Today with Dr Neil Love: Management of Cholangiocarcinoma and Other Biliary Tract Cancers Jul 21, 2022

Show notes

Featuring an interview with Professor Juan Valle, including the following topics:

Immunotherapy for patients with biliary tract cancers (BTCs) (0:00)
Etiology and presentation of and recent advances in the management of cholangiocarcinoma (4:18)
Targeting FGFR alterations in cholangiocarcinoma and other BTCs (12:47)
Spectrum and management of toxicities associated with FGFR inhibitors (19:33)
Targeting driver mutations beyond FGFR (28:16)
Case: A man in his early 60s with intrahepatic cholangiocarcinoma, an FGFR2 fusion and an IDH1 R132C mutation (35:53)
Case: A woman in her early 60s with intrahepatic cholangiocarcinoma and an IDH1 mutation that did not respond to third-line ivosidenib (41:49)
Case: A woman in her early 60s with gallbladder cancer who received first-line chemotherapy with pembrolizumab (46:15)

CME information and select publications